Sativex Cancer Drug Trial Poses Barrier To CBD In The Supplement Industry

In reliance on a drug trial that was announced eight years ago, FDA has determined CBD cannot be marketed as a dietary supplement.

FDA could change its mind, but only if it is provided evidence that CBD was marketed as a supplement or conventional food before GW Pharmaceuticals plc announced that a clinical trial had been initiated in the United States to study Sativex, a drug that was used to treat pain in patients who suffered from advanced cancer. The drug is composed mostly of two cannabinoids: CBD and THC, the psychoactive ingredient in marijuana.

Jeff Ventura, an FDA spokesman, referenced the 2007 trial in connection with the agency’s previously announced conclusion in a marijuana Q&A that CBD products are excluded from the definition of a dietary supplement.

That is because products cannot meet the definition of a dietary supplement or conventional food if

...
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.naturalproductsinsider.com/blogs/supplement-law/2015/06/sativex-cancer-drug-trial-poses-barrier-to-cbd-in.aspx